Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice
- 42 Downloads
- 27 Citations
Summary
Preparations of human leukocyte (α) and fibroblast (β) interferon were given intramuscularly to rabbits and monkeys, and circulating interferon was measured. In rabbits, but not in monkeys, a marked difference between the two interferons was noted in that higher titers of circulating antiviral activity were obtained with leukocyte than with fibroblast interferon. In mice, injected interperitoneally, a similar difference could be noted. However, levels of antiviral activity in homogenates of spleens and lungs did not differ between mice injected with either interferon.
Fibroblast interferon that was injected intrathecally in monkeys was found to diffuse throughout the cerebrospinal canal and to reach the serum compartment. Some interferon could also be recovered from the pia mater surrounding the brain hemispheres, but none was found in the deeper layers of the brain.
Keywords
Infectious Disease Interferon Deep Layer Tissue Distribution Antiviral ActivityPreview
Unable to display preview. Download preview PDF.
References
- 1.Billiau, A., de Somer, P.: Clinical use of interferons in viral infections. In:Stringfellow, D. A. (ed.), Interferon and Interferon Inducers, Clinical Applications, 113–144. New York-Basel: Marcel Dekker 1980.Google Scholar
- 2.Billiau, A., de Somer, P., Edy, V. G., de Clercq, E., Heremans, H.: Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrob. Agents Chemother.16, 53–63 (1979).Google Scholar
- 3.Billiau, A., van Damme, J., van Leuven, F., Edy, V. G., de Ley, M., Cassiman, J. J., van den Berghe, H., de Somer, P.: Human fibroblast interferon for clinical trials: production, partial purification, and characterization. Antimicrob. Agents Chemother.16, 49–55 (1979).Google Scholar
- 4.Edy, V. G., Billiau, A., de Somer, P.: Non-appearance of injected fibroblast interferon in the circulation. Lanceti, 451–452 (1978).Google Scholar
- 5.Finter, N B.: Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. J. gen. Virol.5, 419–427 (1969).Google Scholar
- 6.Greenberg, S. B., Harmon, M. W., Couch, R. C.: Exogenous interferon: stability and pharmacokinetics. In:Stringfellow, D. A. (ed.), Interferon and Interferon Inducers, Clinical Applications, 57–87. New York-Basel: Marcel Dekker 1980.Google Scholar
- 7.Habif, D. V., Lipton, R., Cantell, K.: Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc. Soc. exp. Biol. Med.149, 287–289 (1975).Google Scholar
- 8.Heremans, H., Billiau, A., de Somer, P.: Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy. Infect. Immun. (in press, 1980).Google Scholar
- 9.Lucero, M., Magdelenat, H., Billardon, C., Fridman, W. H., Pouillart, P., Cantell, K., Billiau, A., Falcoff, E.: manuscript in preparation.Google Scholar
- 10.Paulson, G., Kapp, J. P.: Movement of sodium-22, radioiodinated protein, and tritiated water from the cisterna magna into the cerebrovascular circulation. J. Neurosurgery27, 138–141 (1967).Google Scholar
- 11.Vilcek, J., Sulea, I. T., Zerebeckyj, I. L., Yip, Y. K.: Pharmacokinetic properties of human fibroblast and leukocyte interferons in rabbits. J. clin. Microbiol.11, 102–105 (1980).Google Scholar
- 12.Stewart II, W. E.: The Interferon System. Wien-New York: Springer 1979.Google Scholar